Halle, Germany and Gent, Belgium
September 15, 2006
Icon Genetics GmbH, a
wholly owned subsidiary of
Bayer Innovation GmbH,
and Bayer Innovation GmbH, a Belgian subsidiary of Bayer
CropScience announce the publication in Proceedings of the
National Academy of Sciences of the USA (A. Giritch et al.,
Proc. Natl. Acad. Sci. USA, pnas. 0606631103, September 2006) of
the third of a series of research papers titled “Rapid
high-yield expression of full-size IgG antibodies in plants
coinfected with noncompeting viral vectors” describing a
new-generation expression technology for plants developed by
Icon and Bayer researchers.
Since the discovery of this technology 17 years ago, the ability
of plants to express full-size human antibodies has not been
exploited because of low yields and the length of time necessary
to generate just small amounts of research material. Using two
different plant viral vectors and transient co-expression
technology, our scientists have developed a process that
provides a high-yield expression of monoclonal antibodies (mabs)
and takes less than two weeks. The method is exemplified by
producing the human tumor-specific monoclonal antibody A5 IgG1.
With yields as high as 0.5 grams of IgG1 per kilogram of plant
material, the proposed process is suitable for the research,
industrial scale-up and rapid manufacture of antibodies for
health care use. It is also applicable in situations requiring
rapid response such as pandemic events.
This new process represents a
significant technical advancement that broadens the versatility
of our second-generation expression platform technology,
magnifection. This transient expression process is used to start
gene amplification in all mature leaves of a plant
simultaneously, leading to high expression levels. It is
indefinitely scalable and can be done on an industrial scale.
This eclectic technology combines the advantages of three
biological systems: (1) vector efficiency and efficient systemic
DNA delivery of Agrobacterium, (2) speed and expression
level/yield of a plant RNA virus, and (3) posttranslational
capabilities and low production costs of plants. The two other
versions of this technology have been described previously by
Icon Genetics researchers in Proceedings of the National Academy
of Sciences of the USA (Marillonnet et al., Proc. Natl. Acad.
Sci. USA, 101, 6852, 2004) and Nature Biotechnology (Marillonnet
et al., Nat. Biotechnol, 23, 718, 2005).
“We are taking the lead in moving plant-made biopharmaceuticals
closer to commercial reality,” says Dr. Wolfgang Plischke,
member of the Board of Management of Bayer AG. “The acquisition
of Icon Genetics not only brought us a potentially disruptive
manufacturing technology but also a highly motivated team of
talented scientists. I am glad to see that their work is now
being integrated into the broader innovation effort at Bayer.”
The Proceedings of the National Academy of Sciences can be
accessed at www.pnas.org.
Icon Genetics, a wholly-owned subsidiary of Bayer Innovation
GmbH, was established in 1999 and has sites in Halle and Munich.
The company is engaged in developing processes for the
biotechnological production of biopharmaceuticals and other
high-value products in plants.
Bayer Innovation GmbH (BIG), headquartered in Düsseldorf, is a
wholly owned subsidiary of Bayer AG. BIG evaluates and develops
new fields of business for the Bayer Group that are in line with
Bayer’s core competencies of health care, nutrition and
high-tech materials and complement its current key areas of
innovation and business.
Bayer CropScience, a subsidiary of Bayer AG with annual sales of
about EUR 6.0 billion, is one of the world’s leading innovative
crop science companies in the areas of crop protection,
non-agricultural pest control, seeds and plant biotechnology.
The company offers an outstanding range of products and
extensive service backup for modern, sustainable agriculture and
for non-agricultural applications.
Bayer BioScience NV located in Ghent, Belgium is one of the
innovation centers of the BioScience Business Group within Bayer
CropScience AG. |